Dermal papilla (DP)cells,located at the base of the hair follicle,have been shown to have hair-
inductive properties,and when cultured DP cells are re-implanted into a patient,they have been
found to promote new hair growth.ICX-TRC,also referred to as the "hairy generation cell"by Dr
Kemp,can work via two methods -by increasing the thickness of hair follicles that are already
present,and by producing brand new follicles.To date,this has been demonstrated in animal
models.Dr Kemp described how a completed phase I study involving seven patients
demonstrated no safety issues,with five of the seven subjects showing increased hair numbers
following treatment.Delivery of these cells is crucial,with a rapid injection making the cells go to
the bottom of the dermis layer,which is useless as the cells need to locate to the keratinocytes on
the superficial surface in order to allow for follicle growth.The optimal delivery method is via a
modified version of the Hamilton syringe,which is now an approved medical device.Phase II
efficacy trials are currently ongoing with this compound,involving approximately 10 patients per
cohort.This program was designed to optimize formulation/delivery of ICX-TRC.The first cohort
has completed enrolment,with six patients being treated.Preliminary data are anticipated to be
released in the second half of 2007.
My automated HM syringe based on the idea of a tatto gun would completely solve this problem. It would not only deliver the cells to an exacting depth in the skin, it would deliver them at a precise rate inside the skin. End of problem. I have actually drawn up the plans for one that will work (very different from a tatto gun in actuality). A potential addition is to alter the timings in the skin to hold slightly longer at certain crucial depths than others. Thus the injection timing would follow a precisely adjustable mathematical curve. Not only is my gun way more accurate than ICX’ methodology, it has way less cell wastage, and delivers way more injections per injection period. Thus it literally pays for itself after the first few applications (and results in way more hair per cm^2 thus delivering much higher patient satisfaction). It also somewhat addresses the dreaded Dr. Gho consistency problem.
I find it almost impossible to believe that ICX has not came to similar conclusions, and they are still experimenting around with inadequate systems that are subject to human inconsistencies and require the need of special training and talent on the part of those who administer the cells.
And how do they plan to perform a proper statisical analysis of their studies when they cannot write down precise depth and timing figures? If they want to market this as a cure anytime soon, they are going to have to start thinking outside the box a little more frequently.
Question:
I wonder if the video of Dr. Washenik on the ARI website demonstrating a Hamilton Syringe delivery to Dr. Stenn is the same type of delivery that Intercytex is using. And, if ARI or Intercytex are now developing a tatoo gun-type delivery system instead.
This keeps the ball rolling. . . .
» Dermal papilla (DP)cells,located at the base of the hair follicle,have been
» shown to have hair-
» inductive properties,and when cultured DP cells are re-implanted into a
» patient,they have been
» found to promote new hair growth.ICX-TRC,also referred to as the "hairy
» generation cell"by Dr
» Kemp,can work via two methods -by increasing the thickness of hair
» follicles that are already
» present,and by producing brand new follicles.To date,this has been
» demonstrated in animal
» models.Dr Kemp described how a completed phase I study involving seven
» patients
» demonstrated no safety issues,with five of the seven subjects showing
» increased hair numbers
» following treatment.Delivery of these cells is crucial,with a rapid
» injection making the cells go to
» the bottom of the dermis layer,which is useless as the cells need to
» locate to the keratinocytes on
» the superficial surface in order to allow for follicle growth.The optimal
» delivery method is via a
» modified version of the Hamilton syringe,which is now an approved medical
» device.Phase II
» efficacy trials are currently ongoing with this compound,involving
» approximately 10 patients per
» cohort.This program was designed to optimize formulation/delivery of
» ICX-TRC.The first cohort
» has completed enrolment,with six patients being
» treated.Preliminary data are anticipated to be
» released in the second half of 2007.
»
» See link
» http://www.terrapinn.com/2008/stemcells/data/07_analysis.pdf
This is an advertising site for paid
advertisers to showcase successful hair restoration results only. It is not the
mandate of this site to engage in the discussion of failed, unsuccessful
procedures, lawsuits, litigations, refunds or complaint cases. Surgical hair
restoration procedures carry risks. Please do thorough research, consult your
own physician and investigate a doctor's background carefully before making a
decision. By proceeding to use our site, you agree to abide by our Terms of Use & Privacy Policy at http://hairsite.com/terms-of-use/ where you can also find a list of HairSite's sponsoring physicians.